Apr 23, 2025 by Bailey G. Salimes, CRTonline.org
According to a sub-analysis of the PROSPECT II trial, patients with recent non-ST elevation myocardial infarction (NSTEMI) and high baseline levels of high-sensitivity C-reactive protein (hsCRP) are more likely to have pan-coronary atherosclerosis and focal high-risk plaques.